Vilacto Bio Unveils Development Programs for LACTOACTIVE iTHER®
Press Release | 09/21/2018
COPENHAGEN, Denmark, Sept. 21, 2018 (GLOBE NEWSWIRE) — Vilacto Bio Inc. (OTC QB:VIBI) has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound.
LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system.
“Our own research suggests, and we firmly believe, that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and others,” said
Vilacto Bio CEO Gert Anderson.
The areas where LACTOACTIVE iTHER® will be developed first include:
A bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA).
An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study)
A vaccine injection for nanoparticle antibody source for a vaccine producer.
A new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.
Gums and candies and mouthwash, toothpaste for people with immune system deficiency, undergoing chemotherapy and suffering from oral inflammation.
These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
Fabriksvej 48
4700 Næstved
Denmark
Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com